search
Back to results

Home-based Heat Therapy for Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2, Heat Exposure

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Thermoneutral water
Hot water
Sponsored by
Montreal Heart Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 45-75 years
  • Diagnosis of type 2 diabetes mellitus ≥1 year
  • Stable medication ≥12 weeks

Exclusion Criteria:

  • Class 3 obesity
  • Hypertension not controled by medication
  • Diagnosis of cardiac, renal and/or pulmonary disease
  • Diagnosis of severe neuropathy and/or retinopathy
  • Insulin therapy
  • Fasting plasma triglycerides >5.0 mmol/L
  • Fasting total cholesterol >7 mmol/l

Sites / Locations

  • Centre ÉPIC, Montreal Heart InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Experimental

Arm Label

Thermoneutral

Heat

Arm Description

Participants will immerse their feet in a foot bath with water maintained at 36°C

Participants will immerse their feet in a foot bath with water maintained at 42°C

Outcomes

Primary Outcome Measures

Hemoglobin A1C (HbA1C)

Secondary Outcome Measures

Insulin resistance (HOMA-IR)
Postprandial metabolism following meal
Quantified over a 6-hour period following the ingestion of a standardized liquid meal
Peripheral endothelial function
Brachial artery flow-mediated dilation
Post-occlusion reactive hyperemia
Reactive hyperemia following 5 minutes of forearm ischemia
Ischemic handgrip exercise
Reactive hyperemia following ischemic handgrip exercise
Arterial stiffness
Carotid-femoral pulse wave velocity
Blood pressure
24-hour ambulatory blood pressure monitoring

Full Information

First Posted
February 7, 2022
Last Updated
December 9, 2022
Sponsor
Montreal Heart Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05269589
Brief Title
Home-based Heat Therapy for Type 2 Diabetes
Official Title
Impact of a Home-based Heat Therapy Intervention on Markers of Cardiometabolic Function in Adults With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 18, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Montreal Heart Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Heat Exposure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Thermoneutral
Arm Type
Sham Comparator
Arm Description
Participants will immerse their feet in a foot bath with water maintained at 36°C
Arm Title
Heat
Arm Type
Experimental
Arm Description
Participants will immerse their feet in a foot bath with water maintained at 42°C
Intervention Type
Other
Intervention Name(s)
Thermoneutral water
Intervention Description
Participants will immerse their feet in a foot bath that contains thermoneutral water
Intervention Type
Other
Intervention Name(s)
Hot water
Intervention Description
Participants will immerse their feet in a foot bath that contains hot water
Primary Outcome Measure Information:
Title
Hemoglobin A1C (HbA1C)
Time Frame
Change from baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Insulin resistance (HOMA-IR)
Time Frame
Change from baseline to 12 weeks
Title
Postprandial metabolism following meal
Description
Quantified over a 6-hour period following the ingestion of a standardized liquid meal
Time Frame
Change from baseline to 12 weeks
Title
Peripheral endothelial function
Description
Brachial artery flow-mediated dilation
Time Frame
Change from baseline to 12 weeks
Title
Post-occlusion reactive hyperemia
Description
Reactive hyperemia following 5 minutes of forearm ischemia
Time Frame
Change from baseline to 12 weeks
Title
Ischemic handgrip exercise
Description
Reactive hyperemia following ischemic handgrip exercise
Time Frame
Change from baseline to 12 weeks
Title
Arterial stiffness
Description
Carotid-femoral pulse wave velocity
Time Frame
Change from baseline to 12 weeks
Title
Blood pressure
Description
24-hour ambulatory blood pressure monitoring
Time Frame
Change from baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 45-75 years Diagnosis of type 2 diabetes mellitus ≥1 year Stable medication ≥12 weeks Exclusion Criteria: Class 3 obesity Hypertension not controled by medication Diagnosis of cardiac, renal and/or pulmonary disease Diagnosis of severe neuropathy and/or retinopathy Insulin therapy Fasting plasma triglycerides >5.0 mmol/L Fasting total cholesterol >7 mmol/l
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Gagnon, PhD
Phone
514-374-1480
Ext
4205
Email
daniel.gagnon.3@umontreal.ca
Facility Information:
Facility Name
Centre ÉPIC, Montreal Heart Institute
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T1N6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Gagnon, PhD
Phone
1-514-374-1480
Ext
4205
Email
daniel.gagnon.3@umontreal.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Home-based Heat Therapy for Type 2 Diabetes

We'll reach out to this number within 24 hrs